# ARANOTE (NCT04736199)

> Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04736199
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bayer
- Conditions: Prostatic Neoplasms
- Interventions: Darolutamide (Nubeqa, BAY1841788); Placebo; Androgen deprivation therapy (ADT)
- Enrollment: 669
- Primary outcome: Radiological Progression-free Survival (rPFS) Assessed by Central Review

## Commentary we found

- X threads: 90
- YouTube: 60
- Podcasts: 30
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=aranote-nct04736199

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04736199", "email": "<work email>"}; the inbox owner confirms by the emailed link.